ERBB2 and gastroesophageal junction adenocarcinoma: HER2 antigen is also overexpressed in ~20% of esophagogastric adenocarcinoma and 89Zr-trastuzumab showed promising results (safe and high-quality images) in patients with HER2 positive tumors (81).